White Paper

Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

By Amy Kissam-Sands,Vice President, Clinical Operations, and Tim Audin Senior Director, Risk Management, Parexel

Risk indentify crossword blocks -iStock-517223530

Risk-Based Quality Management (RBQM) will be the operational foundation of next-generation clinical research. RBQM mandates new ways of thinking and operating that will change the clinical development process, from the concept and design of clinical trials to the infrastructure and methodologies used to conduct them. A broad constellation of regulatory guidance is in progress to inform sponsors as industry implements this far-reaching revolution. In a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: